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Abstract 
We and others have previously shown that polygenic risk score analysis 
(PRS) has considerable predictive utility for identifying those at high 
risk of developing Alzheimer’s disease (AD) with areas under the curve 
of >0.8.  However, by far the greatest determinant of this risk is 
the apolipoprotein E locus with the E4 allele alone giving an AUC of 
~0.68 and the inclusion of the protective E2 allele increasing this to 
~0.69 in a clinical cohort.  An important question is to determine how 
good PRS is at predicting risk in those who do not carry the E4 allele 
(E3 homozygotes, E3E2 and E2E2) and in those who carry neither the 
E4 or E2 allele (i.e. E3 homozygotes).  We have tested this in a cohort of 
pathologically confirmed AD cases and controls by taking out of the 
analysis, those individuals carrying an E4 allele and those carrying 
either an E4 or an E2 allele.  This had surprisingly little effect on the 
PRS (AUC ~ 0.83 [95% CI: 0.80-0.86]).  We carried out an additional 
analyses taking out all SNPs within 1MB of the APOE locus and this had 
no further effect on the AUC.  From a practical perspective this suggests 
that PRS analysis will have predictive utility even in E4 negative 
individuals. 
Introduction 
Polygenic risk score (PRS) analysis enhances the predictability of the 
diagnosis of AD (1).  In a recent PRS analysis, we showed that the area 
under the curve (AUC) in a pathologically confirmed case/control series 
was 0.84 (2).  However, by far the largest contribution to this risk 
analysis is the E4 allele (risk) and the E2 allele (protective) which gave 
AUC of 0.68 (E4 alone) and 0.69 (E4+E2) as compared to overall PRS 
AUC=0.75 in clinical sample (1).  An important practical and theoretical 
consideration is to understand how good PRS is when the risk at 
the APOE locus is removed.  When this was tested in clinical series (1) 
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the AUC was reduced from 0.75 in the whole dataset to 0.65 in E3 
homozygotes.  We determined to test this in our pathological series by 
removing from the analysis, first all E4 carriers and then, all E4 and E2 
carriers from both the case and the control data sets.  In a subsequent 
analysis we repeated these analyses in the same samples removing 
all SNPs from within 1Mb of the APOE locus to ensure we were not 
capturing other risk at this locus. 
Methods 
The sample characteristics of the original dataset used in this study 
were the same as in our previous analysis (3). This project was declared 
IRB exempt (MedstarProject #2003-118) under the Code of Federal 
Regulations, 45 CFR, 46.  The primary data consisted of 1011 cases and 
583 controls.  The total number of imputed single nucleotide 
polymorphisms (SNPs) was 36,481,940. The number of SNPs with Info 
score above 0.8 was 11,016,052.  From these, the number of SNPs with 
MAF>=0.01 was 7,868,100 and these were used in the analysis (see ref 
4). Association analysis was performed for each SNP using logistic 
regression analysis as implemented in snptest (5).  We eliminated first 
all those samples who had an E4 allele (leaving 354 cases and 454 
controls) and then additionally those with both an E4 and an E2 allele 
(leaving 321 cases and 365 controls).   
Results 
The original AUC for the full pathologically confirmed dataset was 0.84, 
when adjusted for the overlap between the training set, used for SNPs 
selection and the pathologically confirmed dataset (2). The original 
unadjusted AUC was 0.866. In this paper, for the full pathologically 
confirmed dataset, we estimate AUC=0.73 [0.71-0.75] for E4 and AUC= 
0.75 [0.73-0.77] for E4 and E2. Removing all individuals with an E4 
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allele only reduced the unadjusted AUC from 0.866 to 0.834 and then 
removing all E2 carriers (i.e. restricting analysis to E3 homozygotes) 
had a further small effect and reduced the AUC to 0.831. Taking out all 
the SNPs at the APOE locus (chr 19:44,400-46,500KB) had no further 
effect on the predictive value.  Thus, in contrast to the results obtained 
with clinical series, the AUC is only marginally reduced by removing 
APOE4 and APOE2 carriers.  
We tested three possible explanations for this finding: first, the people 
who get AD without an E4 allele have more of the AD risk alleles, i.e. 
allele at other loci have a bigger effects in the absence of APOE4;second, 
the effects of APOE and other risk SNPs are independent and third, the 
results are driven by inflation due to the overlap between the discovery 
(IGAP) and test (E3E3 pathologically confirmed AD cases and controls) 
datasets. 
First we ran GWAS analysis with snptest software only for E3E3 cases 
and controls. The majority of the top (IGAP) SNPs did not show 
statistically significant association in this small sample and their effect 
sizes were not higher than the effect sizes in the whole data set (data 
not shown).  This strongly suggests that the E3 homozygotes with 
disease do not have a greater excess of other AD risk alleles.  
Next we counted the numbers of risk and alternative alleles for sets of 
SNPs at different significance thresholds (reported by the IGAP study) 
for each subject in the E3 homozygotes and in the rest of the sample. 
We compared the average numbers (per person) of risk and alternative 
alleles by means of chi-square test for 2x2 table: (Risk Allele - 
Alternative Allele) x (E3 homozygotes – other genotypes). This analysis 
was performed in cases and controls separately as cases in general may 
have more risk alleles than controls. The results are summarized in 
Table 1. The were no significant differences in the mean numbers of 
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risk and alternative alleles per person among E3 homozygotes versus 
the other genotypes in either pathologically confirmed AD cases nor 
pathologically confirmed controls. 
We also compared the prediction accuracy of the best model (PRS for 
SNPs with p-values≤0.5) with and without APOE locus in three 
subsamples, namely E4 carriers (644 cases and 115 controls), E4 and 
E2 carriers (677 cases and 204 controls) and E3 homozygotes (321 
cases and 365 controls). Table 2 shows the estimated AUC in those sub-
samples for the PRS models with more significant SNPs (p≤0.001 in 
IGAP study) and best predictive PRS model (1), combining all available 
independent SNPs with p-values ≤0.5, when APOE region is included 
and excluded. The results clearly show that the PRS prediction accuracy 
is almost the same in any sub-sample, when APOE is excluded. Note that 
the full sample (shown in the second column of Table 3), has the largest 
overlap with IGAP, and therefore the AUC estimate there has the most 
(~2%) inflation (see (2) for details).  
Finally we adjusted our main result  (AUC=0.831 in E3 homozygotes) 
for the overlap with the discovery IGAP dataset using simulation 
approach as described in (2).  The overlap between IGAP dataset and 
our E3 homozygote dataset was 1.3% (686 individuals in E3E3 dataset 
out of 54,162 individuals in the IGAP data). We simulated 1000 times 
effect sizes of the pruned set of SNPs with mean  b~N(BIGAP, 
sd=0.12*SEIGAP), where BIGAP is the beta-coefficient and SEIGAP is the 
standard error for that SNP in the IGAP study, and the coefficient 0.12 
was estimated empirically (see (2) for details). The adjusted AUC and 
the confidence intervals were calculated as average AUC and CI over the 
1000 simulations, AUCADJ = 0.83 [95% CI: 0.80-0.86].   
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Figure 1 shows distribution of standardized PRS of E3E3 cases and 
E3E3 controls. In the group of negative polygenic extreme (PRS smaller 
than -2), there were 17 controls and 0 cases. In the positive extreme 
group (PRS greater than 2), there were 11 cases and 1 control. Looking 
at the extremes  (PRS < -1.5) and (PRS > 1.5), there were 1 case and 49 
controls and 41 cases and 4 controls, respectively. 
Discussion 
Our results show that the prediction accuracy of PRS in the 
pathologically confirmed sample of E3 homozygotes carriers is high and 
equivalent to the prediction accuracy in the samples of in the whole 
dataset.  This finding indicates APOE is an independent risk factor for 
the disease.  This result is in contrast to the PRS observed in clinical 
cohorts where restricting analyses to E3 homozygotes resulted in a 
large reduction in the PRS.  We believe this is likely to be because of 
poor diagnostic accuracy among those labeled as AD in the absence of 
an E4 allele: this interpretation consistent with post mortem follow up 
of Alzheimer clinical trials which suggested a diagnostic inaccuracy of 
up to 25%.  In this context, all results derived from the analysis of 
clinically defined E4 negative cases should be interpreted with caution.  
From a mechanistic perspective, this result suggests that the genetic 
architecture of AD is similar in E3 homozygotes to that in other 
genotypes since a similar proportion of risk is captured by PRS in all 
genotypes.  This result offers little support to the belief that E3 
homozygotes with Alzheimer’s disease have more predisposing variants 
at other loci. 
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Table 1. Comparison of the mean numbers of risk and alternative alleles 
per person in E3 homozygotes vs. other AD in cases and controls. APOE 
region is excluded. 
Cases 
SNP 
selection 
threshold 
E3  homozygotes Other genotypes 
OR P 
Mean No 
of risk 
alleles 
Mean No of 
alternative 
alleles 
Mean No 
of risk 
alleles 
Mean No of 
alternative 
alleles 
0.0001 92.5 63.3 91.0 63.6 1.016 1 
0.001 306.6 282.2 299.9 283.8 1.022 0.859 
0.01 1777.9 1576.4 1766.1 1580.1 1.007 0.874 
0.05 7348.8 6333.3 7315.1 6346.3 1.005 0.794 
0.1 13329.7 11633.7 13300.3 11661.5 1.002 0.805 
0.2 23935.0 21032.8 23868.4 21084.1 1.003 0.701 
0.3 33149.4 29575.3 33081.5 29657.7 1.002 0.673 
0.4 41612.3 37349.4 41561.4 37436.3 1.001 0.729 
0.5 49267.5 44544.9 49197.0 44643.4 1.001 0.697 
 
Controls 
SNP 
selection 
threshold 
E3 homozygotes Other genotypes 
OR P 
Mean No 
of risk 
alleles 
Mean No of 
alternative 
alleles 
Mean No 
of risk 
alleles 
Mean No of 
alternative 
alleles 
0.0001 87.6 66.8 88.4 67.7 0.991 1.00 
0.001 293.8 293.2 292.8 295.4 1.003 0.973 
0.01 1727.4 1621.3 1723.0 1623.0 1.003 0.961 
0.05 7181.6 6461.3 7153.8 6471.3 1.004 0.833 
0.1 13070.4 11836.9 13037.7 11860.3 1.003 0.810 
0.2 23540.4 21344.5 23466.5 21388.0 1.003 0.703 
0.3 32649.2 29969.2 32573.0 30039.3 1.002 0.684 
0.4 41028.5 37805.2 40983.2 37869.4 1.001 0.785 
0.5 48618.4 45048.2 48564.7 45118.6 1.001 0.776 
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Table 2. AUC for PRS models with IGAP-based p-value SNP selection 
thresholds 0.001 and 0.5. These results are not unadjusted for IGAP 
overlap (see text). 
PRS model AUC and 95% Confidence intervals in “[]” 
whole sample E4 carriers E4E2 carriers E3 homozygotes 
PRS with SNPs p≤0.001 
 
0.741 
[0.72-0.78] 
0.616 
[0.56-0.67] 
0.743 
[0.70-0.78] 
0.632 
[0.59-0.67] 
PRS with SNPs p≤0.5  0.866* 
[0.85-0.89] 
0.831 
[0.78-0.88] 
0.868 
[0.84-0.90] 
0.831 
[0.80-0.86] 
PRS with SNPs p≤0.001 
APOE region excluded 
0.637  
[0.61-0.67] 
0.565 
[0.51-0.62] 
0.625 
[0.58-0.67] 
0.646 
[0.61-0.69] 
PRS with SNPs p≤0.5 
APOE region excluded 
0.840 
[0.82-0.86] 
0.821 
[0.77-0.87] 
0.837 
[0.80-0.87] 
0.834 
[0.80-0.86] 
 
* This AUC is reported in (2). 
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Figure 1. Distribution of standardised and PCA adjusted PRS in E3E3 cases 
and controls. 
 
 
